BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Masavuli MG, Wijesundara DK, Torresi J, Gowans EJ, Grubor-Bauk B. Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C. Front Microbiol 2017;8:2413. [PMID: 29259601 DOI: 10.3389/fmicb.2017.02413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Yang G, Chen S, Zhang J. Bioinspired and Biomimetic Nanotherapies for the Treatment of Infectious Diseases. Front Pharmacol 2019;10:751. [PMID: 31333467 DOI: 10.3389/fphar.2019.00751] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
2 Echeverría N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J. In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? . World J Hepatol 2021; 13(10): 1234-1268 [PMID: 34786164 DOI: 10.4254/wjh.v13.i10.1234] [Reference Citation Analysis]
3 Delfi M, Sartorius R, Ashrafizadeh M, Sharifi E, Zhang Y, De Berardinis P, Zarrabi A, Varma RS, Tay FR, Smith BR, Makvandi P. Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. Nano Today 2021;38:101119. [PMID: 34267794 DOI: 10.1016/j.nantod.2021.101119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
4 Syomin BV, Ilyin YV. Virus-Like Particles as an Instrument of Vaccine Production. Mol Biol 2019;53:323-34. [PMID: 32214478 DOI: 10.1134/S0026893319030154] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
5 [DOI: 10.1101/2020.05.14.093054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Pechelyulko A, Andreeva-Kovalevskaya Z, Dmitriev D, Lavrov V, Massino Y, Nagel A, Segal O, Sokolova OS, Solonin A, Tarakanova Y, Dmitriev A. A simple method to purify recombinant HCV core protein expressed in Pichia pastoris for obtaining virus-like particles and producing monoclonal antibodies. Protein Expr Purif 2021;183:105864. [PMID: 33677084 DOI: 10.1016/j.pep.2021.105864] [Reference Citation Analysis]
7 Dobrica MO, van Eerde A, Tucureanu C, Onu A, Paruch L, Caras I, Vlase E, Steen H, Haugslien S, Alonzi D, Zitzmann N, Bock R, Dubuisson J, Popescu CI, Stavaru C, Liu Clarke J, Branza-Nichita N. Hepatitis C virus E2 envelope glycoprotein produced in Nicotiana benthamiana triggers humoral response with virus-neutralizing activity in vaccinated mice. Plant Biotechnol J 2021. [PMID: 34002936 DOI: 10.1111/pbi.13631] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Ströh LJ, Krey T. HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development. Int J Mol Sci 2020;21:E6781. [PMID: 32947858 DOI: 10.3390/ijms21186781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Polyakov D, Sinitsyna E, Grudinina N, Antipchik M, Sakhabeev R, Korzhikov-Vlakh V, Shavlovsky M, Korzhikova-Vlakh E, Tennikova T. Polymer Particles Bearing Recombinant LEL CD81 as Trapping Systems for Hepatitis C Virus. Pharmaceutics 2021;13:672. [PMID: 34067169 DOI: 10.3390/pharmaceutics13050672] [Reference Citation Analysis]
10 Christiansen D, Earnest-Silveira L, Grubor-Bauk B, Wijesundara DK, Boo I, Ramsland PA, Vincan E, Drummer HE, Gowans EJ, Torresi J. Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci Rep 2019;9:9251. [PMID: 31239471 DOI: 10.1038/s41598-019-45461-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
11 Tariq H, Batool S, Asif S, Ali M, Abbasi BH. Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases. Front Microbiol 2021;12:790121. [PMID: 35046918 DOI: 10.3389/fmicb.2021.790121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
12 McConnell M, Lim JK. Hepatitis C Vaccine Development in the Era of Direct-Acting Antivirals. Clin Liver Dis (Hoboken) 2018;12:118-21. [PMID: 30988925 DOI: 10.1002/cld.753] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Yang J, Zhang L, Zhang C, Lu Y. Exploration on the expression and assembly of virus-like particles. Biotechnology Notes 2021;2:51-8. [DOI: 10.1016/j.biotno.2021.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yechezkel I, Law M, Tzarum N. From Structural Studies to HCV Vaccine Design. Viruses 2021;13:833. [PMID: 34064532 DOI: 10.3390/v13050833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci 2020;27:78. [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Venkataraman S, Hefferon K, Makhzoum A, Abouhaidar M. Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer? Vaccines (Basel) 2021;9:761. [PMID: 34358177 DOI: 10.3390/vaccines9070761] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Yamamoto C, Nagashima S, Chuon C, Ko K, Huy Do S, Lim O, Hok S, Svay S, Matsuo J, Katayama K, Takahashi K, Tanaka J. Substitution of the CD81 Binding Site and β-Sandwich Area in E2 of HCV in Cambodia. Viruses 2020;12:E551. [PMID: 32429467 DOI: 10.3390/v12050551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]